Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 316

Similar articles for PubMed (Select 19212959)

1.

Development of novel thiazolopyrimidines as CDC25B phosphatase inhibitors.

Kolb S, Mondésert O, Goddard ML, Jullien D, Villoutreix BO, Ducommun B, Garbay C, Braud E.

ChemMedChem. 2009 Apr;4(4):633-48. doi: 10.1002/cmdc.200800415.

PMID:
19212959
2.

Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B.

George Rosenker KM, Paquette WD, Johnston PA, Sharlow ER, Vogt A, Bakan A, Lazo JS, Wipf P.

Bioorg Med Chem. 2015 Jun 15;23(12):2810-8. doi: 10.1016/j.bmc.2015.01.043. Epub 2015 Jan 31.

PMID:
25703307
3.

Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.

Toledo-Sherman LM, Prime ME, Mrzljak L, Beconi MG, Beresford A, Brookfield FA, Brown CJ, Cardaun I, Courtney SM, Dijkman U, Hamelin-Flegg E, Johnson PD, Kempf V, Lyons K, Matthews K, Mitchell WL, O'Connell C, Pena P, Powell K, Rassoulpour A, Reed L, Reindl W, Selvaratnam S, Friley WW, Weddell DA, Went NE, Wheelan P, Winkler C, Winkler D, Wityak J, Yarnold CJ, Yates D, Munoz-Sanjuan I, Dominguez C.

J Med Chem. 2015 Feb 12;58(3):1159-83. doi: 10.1021/jm501350y. Epub 2015 Jan 23.

PMID:
25590515
4.

Discovery of 2-(cyclohexylmethylamino)pyrimidines as a new class of reversible valosine containing protein inhibitors.

Cervi G, Magnaghi P, Asa D, Avanzi N, Badari A, Borghi D, Caruso M, Cirla A, Cozzi L, Felder E, Galvani A, Gasparri F, Lomolino A, Magnuson S, Malgesini B, Motto I, Pasi M, Rizzi S, Salom B, Sorrentino G, Troiani S, Valsasina B, O'Brien T, Isacchi A, Donati D, D'Alessio R.

J Med Chem. 2014 Dec 26;57(24):10443-54. doi: 10.1021/jm501313x. Epub 2014 Dec 12.

PMID:
25474526
5.

Inhibition of CDC25B phosphatase through disruption of protein-protein interaction.

Lund G, Dudkin S, Borkin D, Ni W, Grembecka J, Cierpicki T.

ACS Chem Biol. 2015 Feb 20;10(2):390-4. doi: 10.1021/cb500883h. Epub 2014 Dec 1.

PMID:
25423142
6.

Design novel inhibitors for treating cancer by targeting Cdc25B catalytic domain with de novo design.

Wu JW, Zhang H, Duan YQ, Dong WL, Cheng XC, Wang SQ, Wang RL.

Comb Chem High Throughput Screen. 2014;17(10):837-47.

PMID:
25360618
7.

Synthesis and biological evaluation of novel thiadiazole amides as potent Cdc25B and PTP1B inhibitors.

Li Y, Yu Y, Jin K, Gao L, Luo T, Sheng L, Shao X, Li J.

Bioorg Med Chem Lett. 2014 Sep 1;24(17):4125-8. doi: 10.1016/j.bmcl.2014.07.055. Epub 2014 Jul 30.

PMID:
25124112
8.

Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate.

Song Y, Lin X, Kang D, Li X, Zhan P, Liu X, Zhang Q.

Eur J Med Chem. 2014 Jul 23;82:293-307. doi: 10.1016/j.ejmech.2014.05.063. Epub 2014 May 27.

PMID:
24922544
9.

Chalcones derivatives as potent Cell division cycle 25B phosphatase inhibitors.

Zhang J, Ji FJ, Gu Y, Zhang XY, Qiao SX.

Pharmacol Rep. 2014 Jun;66(3):515-9. doi: 10.1016/j.pharep.2013.08.016. Epub 2014 Mar 4.

PMID:
24905533
10.
11.

A novel coumarin-quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell death.

Bana E, Sibille E, Valente S, Cerella C, Chaimbault P, Kirsch G, Dicato M, Diederich M, Bagrel D.

Mol Carcinog. 2015 Mar;54(3):229-41. doi: 10.1002/mc.22094. Epub 2013 Oct 24.

PMID:
24155226
12.

Thiuram disulfides as pseudo-irreversible inhibitors of lymphoid tyrosine phosphatase.

Kulkarni RA, Stanford SM, Vellore NA, Krishnamurthy D, Bliss MR, Baron R, Bottini N, Barrios AM.

ChemMedChem. 2013 Sep;8(9):1561-8. doi: 10.1002/cmdc.201300215. Epub 2013 Jul 19.

13.

Discovery of a new class of highly potent inhibitors of acid ceramidase: synthesis and structure-activity relationship (SAR).

Pizzirani D, Pagliuca C, Realini N, Branduardi D, Bottegoni G, Mor M, Bertozzi F, Scarpelli R, Piomelli D, Bandiera T.

J Med Chem. 2013 May 9;56(9):3518-30. doi: 10.1021/jm301879g. Epub 2013 Apr 24.

PMID:
23614460
14.

Synthetic approaches to DNMT inhibitor SGI-1027 and effects on the U937 leukemia cell line.

García-Domínguez P, Dell'aversana C, Alvarez R, Altucci L, de Lera AR.

Bioorg Med Chem Lett. 2013 Mar 15;23(6):1631-5. doi: 10.1016/j.bmcl.2013.01.085. Epub 2013 Jan 30.

PMID:
23402879
15.

Design and synthesis of novel bis-thiazolone derivatives as micromolar CDC25 phosphatase inhibitors: effect of dimerisation on phosphatase inhibition.

Sarkis M, Tran DN, Kolb S, Miteva MA, Villoutreix BO, Garbay C, Braud E.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7345-50. doi: 10.1016/j.bmcl.2012.10.072. Epub 2012 Oct 22.

PMID:
23141909
16.

Arylstibonic acids are potent and isoform-selective inhibitors of Cdc25a and Cdc25b phosphatases.

Mak LH, Knott J, Scott KA, Scott C, Whyte GF, Ye Y, Mann DJ, Ces O, Stivers J, Woscholski R.

Bioorg Med Chem. 2012 Jul 15;20(14):4371-6. doi: 10.1016/j.bmc.2012.05.040. Epub 2012 May 24.

17.

Transcription Factor DLX5 As a New Target for Promising Antitumor Agents.

Timakhov RA, Fedichev PO, Vinnik AA, Testa JR, Favorova OO.

Acta Naturae. 2011 Jul;3(3):47-51.

18.

Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening.

Lavecchia A, Di Giovanni C, Pesapane A, Montuori N, Ragno P, Martucci NM, Masullo M, De Vendittis E, Novellino E.

J Med Chem. 2012 May 10;55(9):4142-58. doi: 10.1021/jm201624h. Epub 2012 May 1.

PMID:
22524450
19.

Dual-Specificity Phosphatase CDC25A/B Inhibitor Identified from a Focused Library with Nonelectrophilic Core Structure.

Tsuchiya A, Hirai G, Koyama Y, Oonuma K, Otani Y, Osada H, Sodeoka M.

ACS Med Chem Lett. 2012 Apr 12;3(4):294-298. Epub 2012 Feb 15.

20.

The synthesis of ethacrynic acid thiazole derivatives as glutathione S-transferase pi inhibitors.

Li T, Liu G, Li H, Yang X, Jing Y, Zhao G.

Bioorg Med Chem. 2012 Apr 1;20(7):2316-22. doi: 10.1016/j.bmc.2012.02.011. Epub 2012 Feb 13.

PMID:
22370342
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk